TY - JOUR
T1 - The Euromelanoma skin cancer prevention campaign in Europe: characteristics and results of 2009 and 2010
AU - Leest, Robert
AU - Vries, Esther
AU - Bulliard, JL
AU - Paoli, J
AU - Peris, K
AU - Stratigos, AJ
AU - Trakatelli, M
AU - Maselis, TJEML
AU - Situm, M
AU - Pallouras, AC
AU - Hercogova, J
AU - Zafirovik, Z
AU - Reusch, M
AU - Olah, J
AU - Bylaite, M
AU - Dittmar, HC
AU - Scerri, L
AU - Correia, O
AU - Medenica, L
AU - Bartenjev, I
AU - Guillen, C
AU - Cozzio, A
AU - Bogomolets, OV
AU - del Marmol, V
PY - 2011
Y1 - 2011
N2 - Background Euromelanoma is a skin cancer education and prevention campaign that started in 1999 in Belgium as Melanoma day. Since 2000, it is active in a large and growing number of European countries under the name Euromelanoma. Objective To evaluate results of Euromelanoma in 2009 and 2010 in 20 countries, describing characteristics of screenees, rates of clinically suspicious lesions for skin cancer and detection rates of melanomas. Methods Euromelanoma questionnaires were used by 20 countries providing their data in a standardized database (Belgium, Croatia, Cyprus, Czech Republic, FYRO Macedonia, Germany, Greece, Hungary, Italy, Lithuania, Luxembourg, Malta, Moldavia, Portugal, Serbia, Slovenia, Spain, Sweden, Switzerland and Ukraine). Results In total, 59 858 subjects were screened in 20 countries. Most screenees were female (64%), median ages were 43 (female) and 46 (male) and 33% had phototype I or II. The suspicion rates ranged from 1.1% to 19.4% for melanoma (average 2.8%), from 0.0% to 10.7% for basal cell carcinoma (average 3.1%) and from 0.0% to 1.8% for squamous cell carcinoma (average 0.4%). The overall positive predictive value of countries where (estimation of) positive predictive value could be determined was 13.0%, melanoma detection rates varied from 0.1% to 1.9%. Dermoscopy was used in 78% of examinations with clinically suspected melanoma; full body skin examination was performed in 72% of the screenees. Conclusion Although the population screened during Euromelanoma was relatively young, high rates of clinically suspected melanoma were found. The efficacy of Euromelanoma could be improved by targeting high- risk populations and by better use of dermoscopy and full body skin examination.
AB - Background Euromelanoma is a skin cancer education and prevention campaign that started in 1999 in Belgium as Melanoma day. Since 2000, it is active in a large and growing number of European countries under the name Euromelanoma. Objective To evaluate results of Euromelanoma in 2009 and 2010 in 20 countries, describing characteristics of screenees, rates of clinically suspicious lesions for skin cancer and detection rates of melanomas. Methods Euromelanoma questionnaires were used by 20 countries providing their data in a standardized database (Belgium, Croatia, Cyprus, Czech Republic, FYRO Macedonia, Germany, Greece, Hungary, Italy, Lithuania, Luxembourg, Malta, Moldavia, Portugal, Serbia, Slovenia, Spain, Sweden, Switzerland and Ukraine). Results In total, 59 858 subjects were screened in 20 countries. Most screenees were female (64%), median ages were 43 (female) and 46 (male) and 33% had phototype I or II. The suspicion rates ranged from 1.1% to 19.4% for melanoma (average 2.8%), from 0.0% to 10.7% for basal cell carcinoma (average 3.1%) and from 0.0% to 1.8% for squamous cell carcinoma (average 0.4%). The overall positive predictive value of countries where (estimation of) positive predictive value could be determined was 13.0%, melanoma detection rates varied from 0.1% to 1.9%. Dermoscopy was used in 78% of examinations with clinically suspected melanoma; full body skin examination was performed in 72% of the screenees. Conclusion Although the population screened during Euromelanoma was relatively young, high rates of clinically suspected melanoma were found. The efficacy of Euromelanoma could be improved by targeting high- risk populations and by better use of dermoscopy and full body skin examination.
U2 - 10.1111/j.1468-3083.2011.04228.x
DO - 10.1111/j.1468-3083.2011.04228.x
M3 - Article
C2 - 21951235
SN - 0926-9959
VL - 25
SP - 1455
EP - 1465
JO - Journal of the European Academy of Dermatology and Venereology
JF - Journal of the European Academy of Dermatology and Venereology
IS - 12
ER -